Your browser doesn't support javascript.
loading
Blepharophimosis with intellectual disability and Helsmoortel-Van Der Aa Syndrome share episignature and phenotype.
Sarli, Camilla; van der Laan, Liselot; Reilly, Jack; Trajkova, Slavica; Carli, Diana; Brusco, Alfredo; Levy, Michael A; Relator, Raissa; Kerkhof, Jennifer; McConkey, Haley; Tedder, Matthew L; Skinner, Cindy; Alders, Mariëlle; Henneman, Peter; Hennekam, Raoul C M; Ciaccio, Claudia; D'Arrigo, Stefano; Vitobello, Antonio; Faivre, Laurence; Weber, Sacha; Vincent-Devulder, Aline; Perrin, Laurence; Bourgois, Alexia; Yamamoto, Toshiyuki; Metcalfe, Kay; Zollino, Marcella; Kini, Usha; Oliveira, Daniela; Sousa, Sergio B; Williams, Denise; Cappuccio, Gerarda; Sadikovic, Bekim; Brunetti-Pierri, Nicola.
Afiliação
  • Sarli C; Department of Translational Medicine, Federico II University of Naples, Naples, Italy.
  • van der Laan L; Department of Human Genetics, Amsterdam Reproduction & Development Research Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Reilly J; Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.
  • Trajkova S; Department of Medical Sciences, University of Torino, Turin, Italy.
  • Carli D; Molecular Biotechnology Center "Guido Tarone", University of Turin, Turin, Italy.
  • Brusco A; Department of Medical Sciences, University of Torino, Turin, Italy.
  • Levy MA; Department of Medical Sciences, University of Torino, Turin, Italy.
  • Relator R; Medical Genetics Unit, Città della Salute e della Scienza University Hospital, Turin, Italy.
  • Kerkhof J; Department of Neurosciences Rita Levi-Montalcini, University of Turin, Turin, Italy.
  • McConkey H; Verspeeten Clinical Genome Centre, London Health Science Centre, London, Ontario, Canada.
  • Tedder ML; Verspeeten Clinical Genome Centre, London Health Science Centre, London, Ontario, Canada.
  • Skinner C; Verspeeten Clinical Genome Centre, London Health Science Centre, London, Ontario, Canada.
  • Alders M; Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.
  • Henneman P; Verspeeten Clinical Genome Centre, London Health Science Centre, London, Ontario, Canada.
  • Hennekam RCM; Greenwood Genetic Center, Greenwood, South Carolina, USA.
  • Ciaccio C; Greenwood Genetic Center, Greenwood, South Carolina, USA.
  • D'Arrigo S; Department of Human Genetics, Amsterdam Reproduction & Development Research Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Vitobello A; Department of Human Genetics, Amsterdam Reproduction & Development Research Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Faivre L; Department of Human Genetics, Amsterdam Reproduction & Development Research Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
  • Weber S; Department of Pediatric Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Vincent-Devulder A; Department of Pediatric Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Perrin L; Department of Genetics, UNICAEN, Caen University Hospital, Normandy University, Caen, France.
  • Bourgois A; Université de Bourgogne, Inserm U1231, Equipe GAD, Dijon, France.
  • Yamamoto T; CHU Dijon Bourgogne, Centre de Génétique, Centre de Référence Maladies Rares "Anomalies du Développement et Syndromes Malformatifs", FHU-TRANSLDAD, Dijon, France.
  • Metcalfe K; Service de Génétique, CHU de Caen-Normandie, Caen, France.
  • Zollino M; Service de Neurologie, CHU de Caen-Normandie, Caen, France.
  • Kini U; Department of Genetics, UNICAEN, Caen University Hospital, Normandy University, Caen, France.
  • Oliveira D; Department of Genetics, UNICAEN, Caen University Hospital, Normandy University, Caen, France.
  • Sousa SB; Department of Genetics, UNICAEN, Caen University Hospital, Normandy University, Caen, France.
  • Williams D; Division of Gene Medicine, Graduate School of Medical Science, Tokyo Women's Medical University, Tokyo, Japan.
  • Cappuccio G; Manchester Centre for Genomic Medicine, St Mary's Hospital, Health Innovation Manchester, Manchester University Foundation NHS Trust, Manchester, UK.
  • Sadikovic B; Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
  • Brunetti-Pierri N; Institute of Genomic Medicine, Department of Life Sciences and Public Health, 'Sacro Cuore' Catholic University of Rome, Rome, Italy.
Am J Med Genet C Semin Med Genet ; : e32089, 2024 Jun 17.
Article em En | MEDLINE | ID: mdl-38884529
ABSTRACT
Blepharophimosis with intellectual disability (BIS) is a recently recognized disorder distinct from Nicolaides-Baraister syndrome that presents with distinct facial features of blepharophimosis, developmental delay, and intellectual disability. BIS is caused by pathogenic variants in SMARCA2, that encodes the catalytic subunit of the superfamily II helicase group of the BRG1 and BRM-associated factors (BAF) forming the BAF complex, a chromatin remodeling complex involved in transcriptional regulation. Individuals bearing variants within the bipartite nuclear localization (BNL) signal domain of ADNP present with the neurodevelopmental disorder known as Helsmoortel-Van Der Aa Syndrome (HVDAS). Distinct DNA methylation profiles referred to as episignatures have been reported in HVDAS and BAF complex disorders. Due to molecular interactions between ADNP and BAF complex, and an overlapping craniofacial phenotype with narrowing of the palpebral fissures in a subset of patients with HVDAS and BIS, we hypothesized the possibility of a common phenotype-specific episignature. A distinct episignature was shared by 15 individuals with BIS-causing SMARCA2 pathogenic variants and 12 individuals with class II HVDAS caused by truncating pathogenic ADNP variants. This represents first evidence of a sensitive phenotype-specific episignature biomarker shared across distinct genetic conditions that also exhibit unique gene-specific episignatures.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article